- Home
- MRNA vs ABEV Comparison
MRNA vs ABEV Comparison
Compare MRNA & ABEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | ABEV |
|---|---|---|
| Founded | 2010 | 1885 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 51.2B |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MRNA | ABEV |
|---|---|---|
| Price | $221.44 | $2.69 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 23 | 11 |
| Target Price | ★ $138.37 | $3.30 |
| AVG Volume (30 Days) | 16.5M | ★ 25.0M |
| Earning Date | 11-06-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 4.40% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $8.13 | $2.62 |
| Revenue Next Year | $16.26 | $5.23 |
| P/E Ratio | ★ N/A | $16.99 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $2.28 |
| 52 Week High | $254.48 | $3.45 |
Technical Indicators
Market Signals| Indicator | MRNA | ABEV |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 30.05 |
| Support Level | $45.39 | N/A |
| Resistance Level | $254.48 | $3.28 |
| Average True Range (ATR) | 23.18 | 0.09 |
| MACD | -3.74 | -0.07 |
| Stochastic Oscillator | 55.92 | 7.64 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About ABEV Ambev S.A.
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving AB InBev a controlling interest of 62%.